Partha Seshaiah

Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America.

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.